Anti-inflammatory activity of a systemic sting inhibitory non-nucleotide
Ended Project Grant Awarded Last action
- Award ID
- R41AI167270
- Recipient
-
Stinginn, LLC UEI PJV5A55KF6T5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $600,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Florida, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cellular innate immune sensors, such as sting (stimulator of interferon genes), have evolved to detect microbial infection of the cell. Sting controls the potent cytosolic DNA-stimulated innate immune pathways and is activated by cyclic dinucleotides (cdns) such as cyclic DI-GMP and cyclic-DI-AMP secreted by intracellular bacteria following infection. Alternatively, sting can be activated by cyclic GMP-AMP (cgamp) generated by a cellular cgamp synthase cgas (MB21D1) after association with aberrant cytosolic dsdna species, which can include microbial DNA or self-DNA leaked from the nucleus. Association with cdns enables sting to activate the production of type i interferon (IFN) and pro-inflammatory cytokines, which facilitate adaptive immunity. The activation of sting is critical for protection against microbial infection and cancer. However, chronic sting activation is a leading cause of autoinflammatory disease such as severe systemic lupus erythematosus (SLE), sting associated vasculopathy with onset in infancy (savi) inflammation of the GUT, tissue transplant rejection and others. Here, we describe a new generation of novel small sting antagonists that inhibit sting signaling, for evaluation as anti-inflammatory therapeutic agents. The compounds have been generated by stinginn LLC, based in miami, in collaboration with the university of miami school of medicine, FL.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $300,000 | |
| Original award | $300,000 |
Quick answers
Who received award R41AI167270?
R41AI167270 was awarded to Stinginn, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 17, 2021.
How much is award R41AI167270 worth?
$600,000 has been obligated on R41AI167270.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award